GSK Cuts Key Drug Prices in Kenya

GSK's decision to cut prices in the Kenya is part of a strategy to improve patient access to medicines.

UK-based drugmaker GlaxoSmithKline is to reduce the prices of essential drugs in Kenya and other developing countries as part of a strategy to improve patient access to medicines.

GSK East Africa managing director John Musunga said at a briefing that the Kenyan unit would cut prices of essential drugs by as much as 50% to boost volumes. Drugs include Avamys, an asthma medication, which has already dropped 40% in price since last year.

GSK is shifting its focus from a high-margin, low-volume drive to a lower margin, high business model, the high prices of medicines have been a key barrier to patients accessing quality medicines. "Reducing prices of antibiotics, asthma medici